Hospital
Southwest Louisiana Hospital Association INC
Southwest Louisiana Hospital Association INC was paid $42.84M by Medicaid between Jan 2018 and Dec 2024, across 357 billing codes. Its largest line is 99284, emergency room visit (serious) — 18% of everything it billed.
33Billing provider infoSOUTHWEST LOUISIANA HOSPITAL ASSOCIATION INC
LAKE CHARLES, LA 70601
LAKE CHARLES, LA 70601
33aNPI1972549855assigned 06/21/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$42.84M
24GClaims1,334,605
24DCodes billed357
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Louisiana
Rank by total paid#11 of 96
Median peer was paid$5.17M
This provider vs. median8.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official JOHNSON, DAWN controls 15+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 307,993 | $5.70M | |
| 2019 | 229,229 | $4.91M | |
| 2020 | 106,856 | $3.32M | |
| 2021 | 152,642 | $6.21M | |
| 2022 | 194,913 | $8.57M | |
| 2023 | 189,043 | $8.37M | |
| 2024incomplete | 153,929 | $5.76M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 18% | 45,790 | 41,314 | $7.80M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 15% | 28,797 | 25,935 | $6.36M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 7.9% | 38,758 | 35,874 | $3.40M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 5.2% | 82,222 | 73,429 | $2.23M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.9% | 3,966 | 3,565 | $2.08M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 3.3% | 38,148 | 34,008 | $1.43M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.6% | 5,899 | 5,298 | $1.11M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.6% | 4,804 | 4,179 | $1.10M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.3% | 18,387 | 17,292 | $966K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 2.2% | 28,415 | 22,850 | $928K |
| J9271 | Injection, pembrolizumab, 1 mg | 1.9% | 265 | 143 | $830K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 1.8% | 28,273 | 25,789 | $781K |
345 more codes
| 80050 | General health panel | 1.6% | 18,124 | $680K |
| 80053 | Comprehensive metabolic panel | 1.6% | 85,276 | $664K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.5% | 18,298 | $639K |
| 71045 | Radiologic examination, chest; single view | 1.3% | 25,027 | $545K |
| C1776 | Joint device (implantable) | 1.2% | 444 | $533K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.2% | 96,181 | $521K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 11,520 | $416K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 21,676 | $407K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 3,689 | $368K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 5,380 | $342K |
| J0897 | Injection, denosumab, 1 mg | <1% | 364 | $271K |
| 80061 | Lipid panel | <1% | 22,823 | $259K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 435 | $243K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 5,886 | $236K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 10,044 | $206K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 523 | $199K |
| 59025 | Fetal non-stress test | <1% | 3,997 | $198K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 4,239 | $198K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 3,687 | $176K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 6,536 | $170K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 4,846 | $158K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 4,847 | $158K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 1,152 | $147K |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | <1% | 176 | $145K |
| 87536 | <1% | 1,969 | $132K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 442 | $129K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,808 | $127K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 7,422 | $125K |
| 62323 | <1% | 577 | $118K | |
| 82553 | <1% | 16,581 | $115K | |
| 87486 | <1% | 4,335 | $115K | |
| 27447 | <1% | 74 | $113K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 201 | $107K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 12,352 | $100K |
| 80055 | <1% | 7,559 | $98K | |
| 81001 | <1% | 48,916 | $96K | |
| 84484 | <1% | 12,095 | $91K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 13,686 | $89K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 375 | $87K |
| 96367 | <1% | 2,423 | $85K | |
| 84703 | <1% | 13,263 | $83K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,050 | $81K |
| 80368 | <1% | 5,558 | $78K | |
| 80371 | <1% | 7,101 | $77K | |
| 80346 | <1% | 10,133 | $76K | |
| 82550 | <1% | 17,004 | $76K | |
| 80349 | <1% | 6,652 | $76K | |
| 80373 | <1% | 5,225 | $74K | |
| 80354 | <1% | 6,324 | $74K | |
| 86360 | <1% | 1,919 | $73K | |
| 80353 | <1% | 6,571 | $70K | |
| 80372 | <1% | 4,803 | $70K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,796 | $69K |
| 80363 | <1% | 5,734 | $68K | |
| 80357 | <1% | 5,004 | $68K | |
| 80359 | <1% | 10,269 | $63K | |
| 80348 | <1% | 9,062 | $63K | |
| 80366 | <1% | 4,704 | $63K | |
| 80358 | <1% | 9,240 | $62K | |
| 80356 | <1% | 4,892 | $58K | |
| 83992 | <1% | 9,727 | $57K | |
| 83690 | <1% | 11,293 | $56K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 17,603 | $52K |
| 77412 | <1% | 1,019 | $51K | |
| 80323 | <1% | 6,224 | $51K | |
| 80361 | <1% | 6,556 | $51K | |
| 80355 | <1% | 5,356 | $51K | |
| 80365 | <1% | 6,526 | $50K | |
| 80325 | <1% | 6,939 | $48K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 4,566 | $47K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,663 | $46K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,112 | $46K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,582 | $46K |
| 80345 | <1% | 5,448 | $45K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,952 | $45K |
| 84439 | <1% | 5,456 | $44K | |
| 77336 | <1% | 1,338 | $41K | |
| 80370 | <1% | 3,147 | $40K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,750 | $39K |
| 87501 | <1% | 4,626 | $39K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 1,743 | $39K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 224 | $37K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 6,325 | $37K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 12,618 | $36K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,000 | $36K |
| 80336 | <1% | 4,500 | $35K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 927 | $33K |
| 96417 | <1% | 974 | $33K | |
| 80369 | <1% | 1,945 | $33K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,390 | $33K |
| C1821 | Interspinous process distraction device (implantable) | <1% | 59 | $32K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 6,242 | $32K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 1,662 | $31K |
| 80333 | <1% | 2,234 | $30K | |
| 80338 | <1% | 2,231 | $29K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 894 | $28K |
| 72100 | <1% | 1,755 | $28K | |
| 94010 | <1% | 874 | $27K | |
| 90686 | <1% | 2,170 | $27K | |
| 76801 | <1% | 505 | $26K | |
| 80360 | <1% | 2,599 | $26K | |
| 83880 | <1% | 1,239 | $26K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 2,768 | $24K |
| 94726 | <1% | 431 | $23K | |
| 71250 | <1% | 143 | $23K | |
| 80321 | <1% | 2,260 | $23K | |
| 62321 | <1% | 98 | $22K | |
| 45384 | <1% | 154 | $22K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 615 | $21K |
| 84153 | <1% | 1,259 | $21K | |
| 86592 | <1% | 5,401 | $20K | |
| 86803 | <1% | 1,814 | $20K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 14,429 | $19K |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 398 | $19K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 121 | $19K |
| J2704 | Injection, propofol, 10 mg | <1% | 15,462 | $19K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 4,671 | $19K |
| 84702 | <1% | 1,340 | $18K | |
| 86481 | <1% | 310 | $18K | |
| 82570 | <1% | 4,180 | $17K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 6,689 | $17K |
| 20610 | <1% | 468 | $17K | |
| 81003 | <1% | 10,339 | $16K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 155 | $16K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 71 | $15K |
| 87340 | <1% | 1,892 | $15K | |
| 77334 | <1% | 71 | $15K | |
| 86480 | <1% | 353 | $14K | |
| 77300 | <1% | 238 | $14K | |
| 76000 | <1% | 1,001 | $14K | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 1,444 | $14K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 6,573 | $14K |
| 80320 | <1% | 3,942 | $13K | |
| 83721 | <1% | 1,659 | $13K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 186 | $13K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,590 | $13K |
| 76942 | <1% | 560 | $12K | |
| 84481 | <1% | 1,211 | $12K | |
| 82043 | <1% | 2,262 | $11K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 4,065 | $11K |
| 82950 | <1% | 2,416 | $11K | |
| 90677 | <1% | 214 | $10K | |
| 83605 | <1% | 1,431 | $10K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 350 | $10K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 262 | $10K |
| 73560 | <1% | 346 | $10K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 41 | $10K |
| 94729 | <1% | 459 | $10K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 5,023 | $10K |
| 97161 | <1% | 197 | $10K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 391 | $9K |
| 80362 | <1% | 894 | $9K | |
| G0378 | Hospital observation service, per hour | <1% | 106 | $9K |
| 85660 | <1% | 1,839 | $9K | |
| 80329 | <1% | 1,745 | $8K | |
| 76830 | Ultrasound, transvaginal | <1% | 146 | $8K |
| 80074 | <1% | 174 | $7K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 408 | $7K |
| 84156 | <1% | 2,494 | $7K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 273 | $7K |
| 74178 | <1% | 16 | $7K | |
| 94664 | <1% | 306 | $7K | |
| 86140 | <1% | 1,819 | $6K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 137 | $6K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,558 | $6K |
| 82274 | <1% | 430 | $6K | |
| 90670 | <1% | 80 | $6K | |
| 87081 | <1% | 1,015 | $6K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,775 | $6K |
| 88304 | <1% | 310 | $6K | |
| 85610 | <1% | 2,006 | $5K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 4,769 | $5K |
| 83986 | <1% | 1,859 | $5K | |
| 82607 | <1% | 397 | $5K | |
| 87522 | Neg quan hep c or qual rna | <1% | 140 | $5K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 110 | $5K |
| 86704 | <1% | 534 | $5K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 972 | $5K |
| 85730 | <1% | 1,554 | $5K | |
| 82728 | <1% | 436 | $5K | |
| 82677 | <1% | 199 | $5K | |
| 84145 | <1% | 278 | $5K | |
| 73130 | <1% | 150 | $4K | |
| 87186 | <1% | 756 | $4K | |
| 85651 | <1% | 1,192 | $4K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 4,127 | $4K |
| 86705 | <1% | 548 | $4K | |
| 73630 | <1% | 160 | $4K | |
| 72131 | <1% | 16 | $4K | |
| 82105 | <1% | 303 | $4K | |
| 86706 | <1% | 514 | $4K | |
| 43235 | <1% | 31 | $4K | |
| 74018 | <1% | 167 | $4K | |
| 87902 | <1% | 13 | $3K | |
| 88141 | <1% | 204 | $3K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,132 | $3K |
| 86812 | <1% | 362 | $3K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 20 | $3K |
| 82947 | <1% | 1,112 | $3K | |
| 85014 | <1% | 1,494 | $3K | |
| 85018 | <1% | 1,494 | $3K | |
| 81005 | <1% | 1,803 | $3K | |
| 85652 | <1% | 1,629 | $3K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 1,545 | $3K |
| 86336 | <1% | 199 | $3K | |
| 72050 | <1% | 46 | $3K | |
| 96415 | <1% | 294 | $3K | |
| 77387 | <1% | 364 | $3K | |
| 90732 | <1% | 54 | $3K | |
| J0735 | Injection, clonidine hydrochloride, 1 mg | <1% | 156 | $3K |
| 82270 | <1% | 970 | $3K | |
| 72040 | <1% | 187 | $3K | |
| 82962 | <1% | 902 | $2K | |
| 82330 | <1% | 307 | $2K | |
| 84460 | <1% | 552 | $2K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 95 | $2K |
| 84450 | <1% | 540 | $2K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 152 | $2K |
| 84550 | <1% | 560 | $2K | |
| A6257 | Transparent film, sterile, 16 sq. in. or less, each dressing | <1% | 346 | $2K |
| 83550 | <1% | 333 | $2K | |
| 87040 | <1% | 276 | $2K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 274 | $2K |
| 43248 | <1% | 20 | $2K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 54 | $2K |
| 83540 | <1% | 399 | $2K | |
| 73562 | <1% | 50 | $2K | |
| 80143 | <1% | 169 | $2K | |
| 81025 | <1% | 292 | $2K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 277 | $2K |
| 76770 | <1% | 25 | $2K | |
| 80179 | <1% | 156 | $2K | |
| 86780 | <1% | 160 | $2K | |
| 73610 | <1% | 55 | $2K | |
| 82803 | <1% | 395 | $2K | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 390 | $2K |
| 90714 | <1% | 100 | $1K | |
| 86850 | <1% | 307 | $1K | |
| 87210 | <1% | 1,052 | $1K | |
| 86003 | <1% | 17 | $1K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 98 | $1K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 44 | $1K |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | <1% | 29 | $1K |
| 86038 | <1% | 117 | $1K | |
| 85613 | <1% | 232 | $1K | |
| 73030 | <1% | 44 | $1K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 317 | $1K |
| 84478 | <1% | 221 | $1K | |
| 94760 | <1% | 671 | $1K | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 152 | $1K |
| 86900 | <1% | 470 | $1K | |
| 82465 | <1% | 338 | $1K | |
| 77290 | <1% | 15 | $1K | |
| 82077 | <1% | 109 | $1K | |
| 86762 | <1% | 100 | $1K | |
| 86160 | <1% | 79 | $1K | |
| 88342 | <1% | 597 | $990.52 | |
| 86200 | <1% | 77 | $966.66 | |
| 72110 | <1% | 13 | $952.32 | |
| 86901 | <1% | 471 | $918.42 | |
| 83735 | <1% | 242 | $898.06 | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 22,281 | $889.70 |
| A4648 | Tissue marker, implantable, any type, each | <1% | 17 | $881.18 |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 28 | $844.26 |
| 85027 | <1% | 162 | $842.01 | |
| 74019 | <1% | 30 | $830.12 | |
| 96523 | <1% | 176 | $823.14 | |
| 87077 | <1% | 162 | $800.68 | |
| 86880 | <1% | 230 | $766.42 | |
| 99201 | <1% | 26 | $753.35 | |
| 87088 | <1% | 143 | $716.28 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 347 | $696.84 |
| 97162 | <1% | 13 | $670.32 | |
| 86609 | <1% | 15 | $632.42 | |
| 76536 | <1% | 12 | $558.72 | |
| 82951 | <1% | 48 | $541.48 | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 64 | $539.72 |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 397 | $539.01 |
| 80076 | <1% | 82 | $530.58 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,521 | $508.52 |
| 90656 | <1% | 60 | $500.04 | |
| 86430 | <1% | 90 | $485.46 | |
| 86606 | <1% | 17 | $482.50 | |
| 82784 | <1% | 27 | $427.80 | |
| 81596 | <1% | 13 | $391.09 | |
| J1626 | Injection, granisetron hydrochloride, 100 mcg | <1% | 103 | $389.84 |
| 85379 | <1% | 48 | $356.30 | |
| 83615 | <1% | 77 | $353.72 | |
| 82565 | <1% | 117 | $353.71 | |
| 86235 | <1% | 14 | $315.33 | |
| 86708 | <1% | 25 | $312.43 | |
| 82247 | <1% | 106 | $305.25 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 43 | $303.92 |
| 85007 | <1% | 125 | $292.98 | |
| 88311 | <1% | 78 | $279.30 | |
| 82378 | <1% | 19 | $273.91 | |
| 86225 | <1% | 14 | $213.78 | |
| 80069 | <1% | 62 | $209.34 | |
| 83970 | <1% | 17 | $208.06 | |
| 86376 | <1% | 12 | $194.04 | |
| 82785 | <1% | 19 | $181.72 | |
| 84295 | <1% | 344 | $172.29 | |
| 84132 | <1% | 343 | $170.50 | |
| 86039 | <1% | 14 | $161.20 | |
| 82435 | <1% | 344 | $160.16 | |
| 86255 | <1% | 27 | $157.80 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 77 | $157.47 |
| 86709 | <1% | 13 | $146.38 | |
| L1830 | Knee orthosis, immobilizer, canvas longitudinal, prefabricated, off-the-shelf | <1% | 14 | $133.00 |
| 17000 | <1% | 17 | $106.65 | |
| 86036 | <1% | 12 | $99.44 | |
| 86001 | <1% | 16 | $94.66 | |
| 86021 | <1% | 18 | $90.30 | |
| 73565 | <1% | 73 | $82.04 | |
| 86364 | <1% | 12 | $77.85 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 71 | $74.59 |
| J0688 | Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg | <1% | 64 | $69.97 |
| C1758 | Catheter, ureteral | <1% | 400 | $66.88 |
| 86431 | <1% | 16 | $62.37 | |
| 84436 | <1% | 17 | $58.60 | |
| 90694 | <1% | 16 | $57.04 | |
| 84479 | <1% | 17 | $56.90 | |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 25 | $48.44 |
| 87339 | <1% | 492 | $46.50 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 16 | $41.16 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 15 | $37.58 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 20 | $13.84 |
| C9898 | Radiolabeled product provided during a hospital inpatient stay | <1% | 26 | $3.46 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 26 | $3.11 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 47 | $2.83 |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,109 | $0.20 |
| 90832 | Psychotherapy session, about 30 minutes | 0% | 383 | $0.00 |
| 90853 | Group psychotherapy (other than of a multiple-family group) | 0% | 13,452 | $0.00 |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 0% | 23 | $0.00 |
| V2787 | Astigmatism correcting function of intraocular lens | 0% | 294 | $0.00 |
| Q0243 | Injection, casirivimab and imdevimab, 2400 mg | 0% | 60 | $0.00 |
| 90472 | Immunization administration, each additional vaccine (list separately) | 0% | 32 | $0.00 |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 0% | 36 | $0.00 |
| 43450 | 0% | 13 | $0.00 | |
| 81511 | 0% | 70 | $0.00 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 33 | $0.00 |
| 90834 | Psychotherapy session, about 45 minutes | 0% | 142 | $0.00 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 13 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 174 | $0.00 |
| 80335 | 0% | 68 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialJOHNSON, DAWN (CHIEF FINANCIAL OFFIER)
| Provider | Location | Paid |
|---|---|---|
| Turning Point Homes, LLC | Mooresville, NC | $31.63M |
| Florence County Disabilities and Special Needs Board | Florence, SC | $28.27M |
| Youth Haven Services, INC. | Reidsville, NC | $4.84M |
| Youth Haven Services, INC. | Reidsville, NC | $3.16M |
| Youth Haven Services, INC. | Greensboro, NC | $3.08M |
| Youth Haven Services, INC. | Reidsville, NC | $2.86M |
| Youth Haven Services, INC. | Walnut Cove, NC | $1.74M |
| Youth Haven Services | King, NC | $1.19M |
| Youth Haven Services, INC. | Reidsville, NC | $799K |
| Youth Haven Services, INC. | King, NC | $634K |
| Youth Haven Services, INC. | Reidsville, NC | $239K |
| Youth Haven Services, INC. | Reidsville, NC | $166K |
| Youth Haven Services, INC. | Burlington, NC | $53K |
| Lebanon General Practice INC | Lebanon, TN | $44K |
| Tensas Community Health Center INC. | Vidalia, LA | $9K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.